Clinical Trial Data Quality In Neurology Studies

Neurology trials are increasingly shifting toward ocular biomarkers like optical coherence tomography and electroretinograms to monitor disease progression and track drug safety. Because the retina and optic nerve function as direct extensions of the central nervous system, these non-invasive assessments capture structural changes before cognitive symptoms surface. However, executing specialized vision tests across multiple clinical sites introduces immense variability. Discrepancies in equipment calibration, inconsistent technician training, and heavy patient travel burdens frequently compromise data quality, ultimately putting regulatory approval and endpoint integrity at risk.

Overcoming these clinical roadblocks requires standardized imaging protocols and decentralized, point-of-need delivery models. Bringing calibrated equipment and specialized clinicians directly to participants eliminates travel friction, and integrating strict quality assurance and real-time electronic data verification safeguards the entire dataset from the start. Request a comprehensive protocol review to identify hidden data risks in your study and secure your trial endpoints.